Munich trial tests resistance training against muscle loss on tirzepatide
The Phase 4 randomized study compares supervised resistance training with usual care, using contractile thigh muscle volume as its primary measure.
PR
By Priya Raman · Science Reporter
Oct 20 08:00 ETSource: ClinicalTrials.gov
The wire
- 01Technical University of Munich registered NCT07777575, a Phase 4 randomized controlled trial that started 7 October 2026 and is recruiting adults with obesity (BMI over 30) treated with the dual GIP/GLP-1 agonist tirzepatide.
- 02Lean mass loss during rapid incretin-driven weight loss is a standing clinical concern, and the trial aims to show whether structured resistance training preserves thigh muscle volume during treatment.
- 03No enrollment size, training protocol or readout date is given in the registration, and results from a single-center investigator trial will take time to report.
From the source
Read at clinicaltrials.govResistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
NCT07777575 · PHASE4 · RECRUITING · Sponsor: Technical University of Munich · Conditions: Obesity (BMI>30).
Source URL https://clinicaltrials.gov/study/NCT07777575
